These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24412029)

  • 1. Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa.
    Jiang L; Wang Q; Shen S; Xiao T; Li Y
    Thromb Res; 2014 Mar; 133(3):501-6. PubMed ID: 24412029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
    Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
    Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
    Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding.
    Nagakura T; Tabata K; Kira K; Hirota S; Clark R; Matsuura F; Hiyoshi H
    Thromb Res; 2013 Aug; 132(2):271-9. PubMed ID: 23827699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
    Qiu X; Wang W; Zhao Z; Sun S; Tang L
    Eur J Pharmacol; 2018 Oct; 836():50-56. PubMed ID: 30125563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
    Tanabe K; Morishima Y; Shibutani T; Terada Y; Hara T; Shinohara Y; Aoyagi K; Kunitada S; Kondo T
    Thromb Haemost; 1999 May; 81(5):828-34. PubMed ID: 10365760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165.
    Hosaka Y; Matsumoto M; Shinozaki M; Ohno T; Yatagai Y; Kamiya M; Kurokawa M; Nishida H; Matsusue T; Mizuguchi K; Ishii H
    Eur J Pharmacol; 2006 Jan; 529(1-3):164-71. PubMed ID: 16316651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
    Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
    Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
    Furugohri T; Isobe K; Honda Y; Kamisato-Matsumoto C; Sugiyama N; Nagahara T; Morishima Y; Shibano T
    J Thromb Haemost; 2008 Sep; 6(9):1542-9. PubMed ID: 18624979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
    Kaku S; Uemura T; Saitoh M; Suzuki K; Iwatsuki Y; Funatsu T; Kawasaki T
    Eur J Pharmacol; 2013 Jan; 699(1-3):40-7. PubMed ID: 23200896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.